Alert, Alert, Alert: Avalaon GloboCare Corp. (ALBT) every 1-2 months has exploded from lows to average 40% gains for savvy traders, and we have been tracking it!
ALBT has been one of the most dependable trades of the last 6 months and our Small Cap tracker has alerted our team that ALBT could be ready for another 40%, 60% or even 100% move!
As a trader, I remember my missed trades more than my winners!
Make sure you don’t regret this alert, pull up ALBT and start your research for Monday trading.
What did our algorithm detect, look at this chart below!
Over the last 6 months there has been 4 major moves offering anywhere from 28% gains to 55%, in a bearish market!
This is the longest period of time, since August, and our tracker has just went GREEN.
Let’s review the basics before I jump in the 3 catalysts that could make ALBT the best trade of 2023.
Avalon GloboCare Company Summary
Company Name: Avalon GloboCare Corp.
Ticker: ALBT
Exchange: NASDAQ
Website: www.avalon-globocare.com
Avalon GloboCare Company Summary:
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.
Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Let’s turn our attention to the top 3 catalysts that could send ALBT skyrocketing for a 5th time in 6 months!
Top 3 Catalysts:
#1 Under Valued and Under The Radar
#2 The Press Is Incredible
#3 A Major Breakthrough with Their Fusion Gene Map Technology
#1 Under Valued and Under The Radar
Can you imagine that this kind of news is going unoticed? ALBT filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.”
That is headline news and we pride ourselves here at Small Cap Exclusive to bring you the diamonds in the rough. That is why we have numerous 1,000%+++ alerts every year, for over 6 years!
Read the full press release below, it is truly captivating!
FREEHOLD, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT).
“We are pleased to be granted this key patent by the USPTO which expands our intellectual property portfolio,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “We have jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology, and this issuance further enhances our position as a leader in immuno-oncology and cellular medicines.”
“The QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT, can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be potentially used in many clinical applications. The resulting soluble, antibody-like cytokine/chemokine decoy receptors derived using the QTY protein design, have many potential applications including mitigation of the ‘cytokine storm’ associated with CV-19 and cellular immunotherapy delivery, as well as broadening the range of therapeutic targets addressable by CAR T-cell therapies,” concluded Dr. Jin.
#2 The Press Is Incredible
Feb. 13, 2023
Avalon GloboCare Announces Closing of Strategic Investment in Laboratory Services MSO, a Leading Clinical Diagnostics and Reference Laboratory Company
Feb. 2, 2023
Avalon GloboCare Partnerships, Completed Capital Raise, And Robust IP Portfolio Expose An Attractive Value Proposition
Jan. 31, 2023
With Multiple Shots On Revenue-Generating Goals, Avalon GloboCare Positions For A Breakout 2023
#3 A Major Breakthrough with Their Fusion Gene Map Technology
Enabling the Development and Commercialization of Companion Diagnostics and Novel Therapeutic Targets for Leukemia Patients
FREEHOLD, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a leading global developer of innovative cell-based technologies and therapeutics and laboratory testing provider, today announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.
“Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Avalon is applying the bioinformatics from the fusion gene map with the goal of accelerating the development and commercialization of companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients. The first diagnostic prototype is expected to enter clinical study and regulatory filing stage during Q3 of 2023. The fusion gene map technology also provides an unprecedented opp. to identify and validate fusion gene products as potential novel therapeutic targets. Additionally, this gives us an opp. to expand Avalon’s R&D pipeline and intellectual property portfolio.”
ALBT Summary:
Top 3 Catalysts:
#1 Under Valued and Under The Radar
#2 The Press Is Incredible
#3 A Major Breakthrough with Their Fusion Gene Map Technology
Remember, ALBT has been so consistent, you could set your watch to the movement!
Averaging 40% gains for our traders and you can see from the chart below, it could be ready again!
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $6,000 from Life Water Media for profiling ALBT. We own ZERO shares in ALBT.
